Zobrazeno 1 - 9
of 9
pro vyhledávání: '"John D. Iuliucci"'
Autor:
Tim Clackson, Frank Wang, John D. Iuliucci, Narayana I. Narasimhan, Roy Pollock, Yaoyu Ning, Scott D. Wardwell, Lori Berk, David Miller, Rachel M. Squillace, Victor M. Rivera
Supplementary Figure 3 from Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a55a658107edbacb04f85646bc213606
https://doi.org/10.1158/1535-7163.22496250.v1
https://doi.org/10.1158/1535-7163.22496250.v1
Autor:
Tim Clackson, Frank Wang, John D. Iuliucci, Narayana I. Narasimhan, Roy Pollock, Yaoyu Ning, Scott D. Wardwell, Lori Berk, David Miller, Rachel M. Squillace, Victor M. Rivera
The mTOR pathway is hyperactivated through oncogenic transformation in many human malignancies. Ridaforolimus (AP23573; MK-8669) is a novel rapamycin analogue that selectively targets mTOR and is currently under clinical evaluation. In this study, we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1569b6d231c9801039f6c0365f86e4e7
https://doi.org/10.1158/1535-7163.c.6535203
https://doi.org/10.1158/1535-7163.c.6535203
Autor:
Tim Clackson, Frank Wang, John D. Iuliucci, Narayana I. Narasimhan, Roy Pollock, Yaoyu Ning, Scott D. Wardwell, Lori Berk, David Miller, Rachel M. Squillace, Victor M. Rivera
Supplementary Figure 1 from Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31157ac1340d347481ad2e92f31f6667
https://doi.org/10.1158/1535-7163.22496256
https://doi.org/10.1158/1535-7163.22496256
Autor:
Tim Clackson, Frank Wang, John D. Iuliucci, Narayana I. Narasimhan, Roy Pollock, Yaoyu Ning, Scott D. Wardwell, Lori Berk, David Miller, Rachel M. Squillace, Victor M. Rivera
Supplementary Figure Legends from Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::439392f02e858cecdc3c943bce799317
https://doi.org/10.1158/1535-7163.22496247
https://doi.org/10.1158/1535-7163.22496247
Autor:
Tim Clackson, Frank Wang, John D. Iuliucci, Narayana I. Narasimhan, Roy Pollock, Yaoyu Ning, Scott D. Wardwell, Lori Berk, David Miller, Rachel M. Squillace, Victor M. Rivera
Supplementary Table 1 from Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29bf4f4d96fd3dfbf968b8c8066295f5
https://doi.org/10.1158/1535-7163.22496244.v1
https://doi.org/10.1158/1535-7163.22496244.v1
Autor:
Tim Clackson, Frank Wang, John D. Iuliucci, Narayana I. Narasimhan, Roy Pollock, Yaoyu Ning, Scott D. Wardwell, Lori Berk, David Miller, Rachel M. Squillace, Victor M. Rivera
Supplementary Figure 2 from Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4eeceb9b398b313ae4df947905f9c06b
https://doi.org/10.1158/1535-7163.22496253
https://doi.org/10.1158/1535-7163.22496253
Autor:
Scott Wardwell, Thomas O'Hare, Tim Clackson, Brian J. Druker, Jeffrey Keats, Qihong Xu, Karin Russian, Victor M. Rivera, John D. Iuliucci, Joseph Snodgrass, Yaoyu Ning, William C. Shakespeare, Amie S. Corbin, Sarah Lamore, Marc Broudy, Frank Wang
Publikováno v:
Blood. 110:1032-1032
Resistance to current Bcr-Abl kinase inhibitors in CML patients is associated with the emergence of Bcr-Abl point mutations, including the T315I variant which represents 15–20% of clinically observed mutants and is resistant to all approved agents
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::31c95b19df84b8f1952d2e35a94e93bc
https://doi.org/10.1182/blood.v110.11.1032.1032
https://doi.org/10.1182/blood.v110.11.1032.1032
Autor:
Ronald F. Gautieri, John D. Iuliucci
Publikováno v:
Journal of pharmaceutical sciences. 60(3)
The results of this investigation indicate that teratogenic effects of high subcutaneous doses of morphine sulfate administered on Day 8 or 9 of gestation in CF-1 mice are not augmented by histamine dihydrochloride or decreased by diphenhydramine. On
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9fa9de131d915d7eae7d06025c1f0386
https://pubmed.ncbi.nlm.nih.gov/4398382
https://pubmed.ncbi.nlm.nih.gov/4398382
Publikováno v:
Annals of Internal Medicine. 109:635
The F(ab')2 fragment of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor (7E3) is a potent inhibitor of both in-vitro platelet aggregation and in-vivo platelet thrombus formation in animal studies. As a first step in assessing the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::792210d33f417c221f44796456606a44
https://doi.org/10.7326/0003-4819-109-8-635
https://doi.org/10.7326/0003-4819-109-8-635